Paul C Grimm, MD
Nephrology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Hospitals listed: Lucile Salter Packard Children'S Hsp at Stanford. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Grimm’s office at (650) 498-7200 to ask if they take your plan before you enroll.
California Medical Board record
Licence A44616 · Current
Licensed to practise in California · since 1988 · expires 2027-06-30 · University of Saskatchewan College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Lucile Salter Packard Children'S Hsp at StanfordPalo Alto, CAChildren · Voluntary non-profit - Private · No emergency departmentPart of Stanford Health Care, which runs 3 hospitalsNo overall ratingNo measure marked better or worse than the national rate
Original Medicare doctor bills
$14,133
Medicare paid this office $14,133 for 20 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 13 | $6,284 | $161 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 16 | $2,874 | $28 |
Who their Medicare patients are
20 Original Medicare patients in 2024. Average age 11 · Under 65 100% · 85 and older 0% · Health risk score 7.52. Sicker patients than 9 in 10 peers; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75%.
The office billed $53,571, Medicare allowed $17,959 and paid $14,133; for 188 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 20 | 188 | 11 | 7.52 | $53,571 | $14,133 |
| 2023 | 15 | 74 | 11 | 6.25 | $25,790 | $7,244 |
| 2022 | 16 | 101 | 14 | 5.60 | $33,613 | $9,372 |
| 2021 | 17 | 84 | 12 | 6.26 | $40,027 | $9,089 |
| 2020 | 18 | 77 | 13 | 5.06 | $40,754 | $7,861 |
| 2019 | 23 | 55 | 15 | 3.80 | $21,333 | $6,520 |
| 2018 | 18 | 38 | 14 | 4.69 | $13,366 | $4,477 |
| 2017 | 25 | 93 | 14 | 6.08 | $30,235 | $9,354 |
| 2016 | 34 | 113 | 17 | 5.63 | $44,157 | $11,392 |
| 2015 | 27 | 101 | 17 | 6.21 | $32,114 | $10,666 |
| 2014 | 24 | 44 | 15 | 4.77 | $17,304 | $4,884 |
| 2013 | 19 | 65 | 13 | 3.53 | $24,891 | $6,157 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2022: 1 service
| Long return visit (40+ min) | 11 | $4,399 | $157 |
2021: 1 service
| Long return visit (40+ min) | 11 | $3,878 | $155 |
2019: 1 service
| Long return visit (40+ min) | 17 | $4,223 | $132 |
2017: 1 service
| Long return visit (40+ min) | 17 | $2,802 | $112 |
2016: 1 service
| Long return visit (40+ min) | 16 | $3,041 | $117 |
2015: 1 service
| Long return visit (40+ min) | 15 | $2,833 | $118 |
2013: 1 service
| Long return visit (40+ min) | 11 | $1,039 | $80 |
Medicaid work
$20,632 in 2024
Medicaid paid $20,632 for 208 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 74 | $12,373 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 32 | $3,189 |
| Service | 77 | $2,626 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 25 | $2,444 |
| 2024 | 208 | 4 | 16 | $20,632 |
| 2023 | 408 | 4 | 19 | $31,701 |
| 2022 | 299 | 4 | 27 | $26,882 |
| 2021 | 226 | 3 | 19 | $22,024 |
| 2020 | 92 | 2 | 20 | $9,959 |
| 2019 | 112 | 2 | 21 | $12,504 |
| 2018 | 53 | 1 | 21 | $4,500 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 74 | $11,202 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 102 | $8,852 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 67 | $6,020 |
| Service | 165 | $5,627 |
2022
| Long return visit (40+ min) | 112 | $16,109 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 70 | $5,622 |
| Service | 93 | $3,171 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 24 | $1,980 |
2021
| Long return visit (40+ min) | 144 | $18,732 |
| Service | 60 | $2,046 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 22 | $1,246 |
2020
| Long return visit (40+ min) | 57 | $7,036 |
| Return visit (30+ min) | 35 | $2,922 |
2019
| Long return visit (40+ min) | 82 | $10,455 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 30 | $2,049 |
2018
| Long return visit (40+ min) | 53 | $4,500 |
Drugs they prescribed that Part D paid
$2,093,821
Pharmacies billed $2,093,821 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 39) in 2024. Too few prescriptions to compare fairly with other clinicians.
0 generic and 37 brand-name prescriptions · $2,093,821 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Procysbi | 22 | $1,983,536 | $90,161 |
| Cystadrops | 12 | $108,168 | $9,014 |
Year by year
| 2024 | 39 | None | 0% (0) | 95% | $2,093,821 |
| 2023 | 35 | None | 0% (0) | 94% | $1,981,110 |
| 2022 | 37 | None | 0% (0) | 92% | $1,960,946 |
| 2021 | 35 | None | 0% (0) | 100% | $2,419,172 |
| 2020 | 21 | None | 0% (0) | 81% | $1,303,123 |
| 2019 | 25 | None | 0% (0) | 68% | $984,615 |
| 2018 | 35 | None | 0% (0) | 69% | $1,586,865 |
| 2017 | 48 | None | 0% (0) | 67% | $1,602,541 |
| 2016 | 60 | None | 0% (0) | 82% | $1,476,898 |
| 2015 | 61 | None | 0% (0) | 67% | $1,079,855 |
| 2014 | 69 | None | 0% (0) | 64% | $727,077 |
| 2013 | 42 | None | 0% (0) | 60% | $149,330 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Procysbi | 22 | $1,891,927 | $85,997 |
| Cystadrops | 11 | $89,144 | $8,104 |
2022: 1 drug
| Procysbi | 22 | $1,872,548 | $85,116 |
2021: 1 drug
| Procysbi | 24 | $2,343,485 | $97,645 |
2020: 1 drug
| Procysbi | 17 | $1,302,418 | $76,613 |
2019: 1 drug
| Procysbi | 15 | $970,264 | $64,684 |
2018: 1 drug
| Procysbi | 23 | $1,582,795 | $68,817 |
2017: 1 drug
| Procysbi | 25 | $1,578,775 | $63,151 |
2016: 2 drugs
| Procysbi | 26 | $1,364,308 | $52,473 |
| Cystaran | 19 | $99,371 | $5,230 |
2015: 3 drugs
| Procysbi | 23 | $1,040,167 | $45,225 |
| Cystaran | 18 | $37,238 | $2,069 |
| Clonidine | 11 | $2,153 | $196 |
2014: 2 drugs
| Procysbi | 21 | $697,285 | $33,204 |
| Clonidine | 13 | $3,077 | $237 |
2013: 1 drug
| Valcyte | 15 | $47,737 | $3,182 |
Money from drug and device companies
$4,893 in 2025
| 2025 | 2 | 12 | $3,500 | $4,893 |
| 2024 | 1 | 16 | $14,651 | $17,134 |
| 2023 | 6 | 9 | $3,984 | $4,338 |
| 2022 | 2 | 26 | $25,806 | $28,656 |
| 2021 | 2 | 5 | $11,874 | $12,012 |
| 2020 | 1 | 3 | $12,213 | $12,213 |
| 2019 | 5 | 23 | $17,281 | $19,266 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Travere Therapeutics | Filspari | $4,785 | 11 payments
|
| Apellis Pharmaceuticals | None | $108 | 1 payment
|
See all 12 published payments
| Travere Therapeutics | Travel · 2025-12-16 | None | $76 |
| Travere Therapeutics | Consulting · 2025-12-16 | None | $3,500 |
| Travere Therapeutics | Meals · 2025-12-16 | None | $34 |
| Travere Therapeutics | Travel · 2025-12-16 | None | $69 |
| Travere Therapeutics | Meals · 2025-12-05 | Filspari | $32 |
| Travere Therapeutics | Meals · 2025-12-05 | Filspari | $124 |
| Travere Therapeutics | Travel · 2025-12-05 | Filspari | $315 |
| Travere Therapeutics | Travel · 2025-12-05 | Filspari | $470 |
| Travere Therapeutics | Meals · 2025-12-05 | Filspari | $32 |
| Travere Therapeutics | Meals · 2025-12-05 | Filspari | $62 |
| Travere Therapeutics | Meals · 2025-12-05 | Filspari | $71 |
| Apellis Pharmaceuticals | Meals · 2025-11-20 | None | $108 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $17,134
| Amgen | Procysbi | $17,134 | 16 payments
|
2023: $4,338
| Horizon Therapeutics plc | Procysbi | $4,004 | 3 payments
|
| Alnylam Pharmaceuticals | Oxlumo | $105 | 1 payment
|
| Recordati Rare Diseases Inc. | Cystadrops | $89 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $65 | 1 payment
|
| Novartis Pharmaceuticals | None | $47 | 1 payment
|
| Genzyme | None | $28 | 1 payment
|
2022: $28,656
| Horizon Therapeutics plc | Procysbi | $28,534 | 25 payments
|
| Alexion Pharmaceuticals | Ultomiris | $122 | 1 payment
|
2021: $12,012
| Horizon Therapeutics plc | Procysbi | $11,874 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $138 | 2 payments
|
2020: $12,213
| Horizon Therapeutics plc | Procysbi | $12,213 | 3 payments
|
2019: $19,266
| Horizon Therapeutics plc | Procysbi | $13,375 | 11 payments
|
| Recordati Rare Diseases Inc. | None | $3,333 | 1 payment
|
| Genentech | Non-Covered Product | $2,070 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $366 | 3 payments
|
| Veloxis Pharmaceuticals | Envarsus | $121 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Alexion Pharmaceuticals, Inc. · A Phase 3, Open-Label, Multicenter Study of Alxn1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (Ahus) · 2020 | Their institution | $9,450 |
| Alexion Pharmaceuticals, Inc. · A Phase 3, Open-Label, Multicenter Study of Alxn1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (Ahus) · 2021 | Their institution | $8,557 |
Professional record
- NPI
- 1184705386
- Licence
- CA A44616California A44616: Current · expires 2027-06-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080P0210X (2080P0210X); Pediatrics (208000000X)
- Mailing address
- 300 Pasteur Dr, G306, Mc5208, Stanford, CA, 94305
- NPI first listed
- 2006-10-17
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305